The chapter is dedicated to the issues of clinical oncoproteomics, its role and
place in contemporary medicine in general, and in oncology in particular. We attempted
to systemize the views of different researchers and detect information and significance
of the evidence of clinical oncoproteomics for the development of novel methods of
diagnostics and cancer therapy using cell, genome and post-genome technologies. The
chapter summarizes contemporary ideas of tumor carcinogenesis centrally laying
emphasis on the theoretical, methodological and technic the aspects of the novel
medical approach of personalized proteome-based cell therapy of neoplasms.
Experience of mapping, proteome and transcriptome profiling of postnatal regional
progenitors and cancer stem cells in different cancer cases, methods of bioinformatical
processing and mathematical modeling of the results have been elucidated. The basic
mathematical tool kit to detect targets for the regulation of proliferative and
reproductive functions of cancer stem cell in the tumor and the way to obtain target
individually tailored anti-cancer proteome-modified cell preparations have been
highlighted. Further, the mechanisms, limitations and prospects of application of these
biotechnologies based on clinical oncoproteomics in the target therapy of cancer and
recent patents have also been discussed.
Keywords: Cancer cells, cancer immune therapy, cancer stem cells, cancer, cell signaling, chemical induction, clinical proteomics, glioblastoma, intracellular
signal transduction pathways, multipotent mesenchymal stromal cells, neoplasm,
neural stem cells, personalized cancer therapy, proteome mapping, proteome,
proteomics, stem cells, target therapy, tumor, U87 glioblastoma.
